Literature DB >> 25773391

MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2.

Ya-Zeng Huang1, Jun Zhang, Hai-Yu Shao, Jin-Ping Chen, Hong-Ying Zhao.   

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs of 19-25 nt that can regulate gene expression at a posttranscriptional level. Increasing evidence indicates that miRNAs participate in almost every step of cellular processes and are often aberrantly expressed in human cancer. The aim of this study was to investigate the functional significance of miR-191 and to identify its possible target genes in osteosarcoma cells. Here, we found that the expression level of miR-191 was increased in osteosarcoma tissues in comparison with the adjacent normal tissues. The enforced expression of miR-191 was able to promote cell proliferation in Saos-2 and MG62 cells, while miR-191 antisense oligonucleotides blocked cell proliferation. At the molecular level, our results further revealed that expression of tumor suppressor gene, checkpoint kinase 2, was negatively regulated by miR-191. Therefore, we consider that miR-191 act as an onco-MicroRNA for osteosarcoma and it would offer a new way in molecular targeting cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25773391     DOI: 10.1007/s13277-015-3290-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

Review 1.  The evolution of gene regulation by transcription factors and microRNAs.

Authors:  Kevin Chen; Nikolaus Rajewsky
Journal:  Nat Rev Genet       Date:  2007-02       Impact factor: 53.242

2.  PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2.

Authors:  Shutong Yang; Christin Kuo; John E Bisi; Myung K Kim
Journal:  Nat Cell Biol       Date:  2002-11       Impact factor: 28.824

3.  Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors.

Authors:  Carl W Miller; Takayuki Ikezoe; Utz Krug; Wolf-K Hofmann; Sigal Tavor; Vijaya Vegesna; Kunihiro Tsukasaki; Seisho Takeuchi; H Phillip Koeffler
Journal:  Genes Chromosomes Cancer       Date:  2002-01       Impact factor: 5.006

4.  Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma.

Authors:  Yinghua He; Ying Cui; Wei Wang; Jun Gu; Shicheng Guo; Kelong Ma; Xiaoying Luo
Journal:  Neoplasia       Date:  2011-09       Impact factor: 5.715

5.  Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.

Authors:  J Falck; C Lukas; M Protopopova; J Lukas; G Selivanova; J Bartek
Journal:  Oncogene       Date:  2001-09-06       Impact factor: 9.867

6.  Overexpression of microRNA miR-30a or miR-191 in A549 lung cancer or BEAS-2B normal lung cell lines does not alter phenotype.

Authors:  Santosh Kumar Patnaik; Eric Kannisto; Sai Yendamuri
Journal:  PLoS One       Date:  2010-02-15       Impact factor: 3.240

Review 7.  CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

Authors:  Laurent Antoni; Nayanta Sodha; Ian Collins; Michelle D Garrett
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

8.  Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

Authors:  Vidar Staalesen; Jacob Falck; Stephanie Geisler; Jirina Bartkova; Anne-Lise Børresen-Dale; Jiri Lukas; Johan Richard Lillehaug; Jiri Bartek; Per Eystein Lønning
Journal:  Oncogene       Date:  2004-11-04       Impact factor: 9.867

9.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

10.  Prognostic Values of microRNAs in Colorectal Cancer.

Authors:  Yaguang Xi; Andrea Formentini; Minchen Chien; David B Weir; James J Russo; Jingyue Ju; Marko Kornmann; Jingfang Ju
Journal:  Biomark Insights       Date:  2006
View more
  13 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  miR-1297 regulates neural stem cell differentiation and viability through controlling Hes1 expression.

Authors:  Jiaolin Zheng; Dan Yi; Xiaodong Shi; Huaizhang Shi
Journal:  Cell Prolif       Date:  2017-05-02       Impact factor: 6.831

Review 3.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

4.  miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.

Authors:  Shuguang Zhou; Bing Wang; Jun Hu; Yucheng Zhou; Mengzhen Jiang; Mingyu Wu; Liming Qin; Xuming Yang
Journal:  Tumour Biol       Date:  2016-01-13

5.  MicroRNA-191-5p exerts a tumor suppressive role in renal cell carcinoma.

Authors:  Peijie Chen; Xiang Pan; Liwen Zhao; Lu Jin; Canbin Lin; Jing Quan; Tao He; Liang Zhou; Xueling Wu; Yong Wang; Liangchao Ni; Shangqi Yang; Yongqing Lai
Journal:  Exp Ther Med       Date:  2017-11-28       Impact factor: 2.447

Review 6.  Small molecules targeting microRNA for cancer therapy: Promises and obstacles.

Authors:  Di Wen; Michael Danquah; Amit Kumar Chaudhary; Ram I Mahato
Journal:  J Control Release       Date:  2015-08-06       Impact factor: 9.776

7.  MicroRNA-610 suppresses osteosarcoma oncogenicity via targeting TWIST1 expression.

Authors:  Chi Jin; Yongjian Feng; Yongjian Ni; Zhonglin Shan
Journal:  Oncotarget       Date:  2017-04-11

8.  Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.

Authors:  Amanda Tivnan; Tatjana Heilinger; Joanne M Ramsey; Gemma O'Connor; Jenny L Pokorny; Jann N Sarkaria; Brett W Stringer; Bryan W Day; Andrew W Boyd; Ella L Kim; Holger N Lode; Sally-Ann Cryan; Jochen H M Prehn
Journal:  Oncotarget       Date:  2017-03-07

9.  LncRNA CCAT2 promoted osteosarcoma cell proliferation and invasion.

Authors:  Lihua Yan; Xiangkun Wu; Xianzhe Yin; Feng Du; Yongxi Liu; Xunmeng Ding
Journal:  J Cell Mol Med       Date:  2018-03-04       Impact factor: 5.310

10.  Identification of miRNA and genes involving in osteosarcoma by comprehensive analysis of microRNA and copy number variation data.

Authors:  Tao Luo; Xiangli Yi; Wei Si
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.